{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-21-000098","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2021-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.539900+00:00","generated_at":"2026-06-29T03:36:19.515371+00:00","sec_items":["5.02","5.07","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunovant appoints Renee Barnett as CFO; shareholders approve option repricing","bullets":["Renee Barnett appointed CFO effective Oct 4, 2021; base salary $400K, signing bonus $500K, RSU bonus grant of 59,500 shares vesting Jan 1, 2022.","Barnett also receives options for 333,000 shares and RSUs for 143,000 shares vesting over four years.","Annual meeting results: 3 directors elected, EY ratified as auditor, say-on-pay frequency every year approved.","Stockholders approved repricing of certain outstanding stock options under 2019 Equity Incentive Plan.","Company plans to initiate pivotal MG trial and reinitiate TED and WAIHA programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-21-000098","json":"https://secwatch.observer/filing/0001764013-21-000098.json","markdown":"https://secwatch.observer/filing/0001764013-21-000098.md","text":"https://secwatch.observer/filing/0001764013-21-000098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000098/0001764013-21-000098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000098/imvt-20210909.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T03:36:19.515371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68c379cdb0","claim":"Eric Venker was elected as Director at Immunovant, Inc..","evidence_excerpt":"Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000098/0001764013-21-000098-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6b8cc82066","claim":"Atul Pande was elected as Director at Immunovant, Inc..","evidence_excerpt":"Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000098/0001764013-21-000098-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a0c81ebb54","claim":"Renee Barnett was appointed as Chief Financial Officer at Immunovant, Inc..","evidence_excerpt":"On September 14, 2021, Renee Barnett was appointed the Chief Financial Officer of Immunovant, Inc. effective October 4, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000098/0001764013-21-000098-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"c186edaae8","claim":"Andrew Fromkin was elected as Director at Immunovant, Inc..","evidence_excerpt":"Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000098/0001764013-21-000098-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e9740e6067","claim":"Frank M. Torti was elected as Director at Immunovant, Inc..","evidence_excerpt":"Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401321000098/0001764013-21-000098-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}